Drugs / DAW2020
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04538755 Comparator | Nov 2020 → May 2025 overdue | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAW2020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04538755 ↗ |
| Route | Oral | “DAW2020 oral capsule” NCT04538755 ↗ |